Financial Performance Highlights (Quarter Ended 30-Jun-26)

  • Revenue from operations: ₹4,696.84 lakhs (compared to ₹3,957.56 lakhs in Q1 FY26)
  • Other Income: ₹55.98 lakhs
  • Total Income: ₹4,752.82 lakhs
  • Total Expenses: ₹4,429.51 lakhs
  • Profit before tax: ₹323.32 lakhs (compared to ₹228.87 lakhs in Q1 FY26)
  • Tax Expense:
  • Current Tax: ₹67.60 lakhs
  • Deferred Tax: ₹19.16 lakhs
  • Net Profit after tax: ₹236.56 lakhs (compared to ₹149.86 lakhs in Q1 FY26)
  • Earnings per share (Basic): ₹1.88 (compared to ₹1.19 in Q1 FY26)
  • Earnings per share (Diluted): ₹1.88 (compared to ₹1.16 in Q1 FY26)
  • Paid-up equity share capital: ₹1,258.90 lakhs (Face Value of ₹10 each)

Comparative Financials

Quarter Ended 30-Jun-26 vs 30-Jun-25:

  • Revenue growth: 19% YoY (₹4,696.84 lakhs vs ₹3,957.56 lakhs)
  • Net profit growth: 58% YoY (₹236.56 lakhs vs ₹149.86 lakhs)
  • EPS (Basic) growth: 58% YoY (₹1.88 vs ₹1.19)

Quarter Ended 30-Jun-26 vs 31-Mar-26:

  • Revenue growth: 3% QoQ (₹4,696.84 lakhs vs ₹4,576.61 lakhs)
  • Net profit growth: 26% QoQ (₹236.56 lakhs vs ₹187.69 lakhs)
  • EPS (Basic) growth: 26% QoQ (₹1.88 vs ₹1.49)

Warrant Forfeiture Event

The Company disclosed that on 5th December 2024, it had issued and allotted 15,00,000 Convertible share warrants at an issue price of ₹174 per warrant. The warrant holders paid 25% of the issue price (₹652.50 lakhs) upfront. These warrants were convertible into equity shares of face value ₹10 each at a premium of ₹164 upon payment of the balance 75% within eighteen months from the date of allotment.

During the quarter ended 30th June 2026, the conversion period expired on 5th June 2026. The warrant holders did not exercise their option to convert by remitting the balance 75% of the warrant exercise price within the stipulated period. Consequently, the Board of Directors at its meeting held on 18th June 2026 approved the forfeiture of these unexercised warrants. The upfront amount of ₹652.50 lakhs received at the time of allotment has been forfeited and transferred to Capital Reserve in accordance with the terms of issue and applicable regulatory requirements.

Merger Update

The Board of Directors had approved a Scheme of Arrangement for merger with Vitanosh Ingredients Private Limited on 23rd October 2024. The Company received approval from BSE Limited on 28th March 2025, and shareholders approved the scheme at an Extraordinary General Meeting held on 28th March 2026. The scheme is currently pending final approvals from the Securities and Exchange Board of India (SEBI) and the National Company Law Tribunal (NCLT). No effect of the scheme has been given in the financial results for the quarter ended 30th June 2026 pending receipt of these regulatory approvals.

Auditor's Review

The statutory auditors, D M K H & Co. (Firm Registration No.: 116886W), conducted a limited review of the financial results in accordance with Standard on Review Engagements (SRE) 2410 issued by the Institute of Chartered Accountants of India. The auditors concluded that nothing has come to their attention that causes them to believe that the financial results are not prepared in accordance with applicable Indian Accounting Standards and accounting principles generally accepted in India, and that they contain the required disclosures under Regulation 33 of SEBI LODR Regulations.

Additional Information

  • The Company operates in one reportable business segment: 'Pharmaceuticals'
  • Figures for the previous reporting period have been reclassified/regrouped wherever necessary
  • The numbers for quarter ended March 31, 2026 are balancing numbers between audited full-year numbers and published reviewed nine-month numbers
  • The complete financial results are available on www.bseindia.com and www.lactoseindialimited.com